KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $9.8 billion.

  • Eli Lilly's Cash & Equivalents rose 19064.71% to $9.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 billion, marking a year-over-year increase of 19064.71%. This contributed to the annual value of $3.3 billion for FY2024, which is 1595.83% up from last year.
  • As of Q3 2025, Eli Lilly's Cash & Equivalents stood at $9.8 billion, which was up 19064.71% from $3.4 billion recorded in Q2 2025.
  • Eli Lilly's 5-year Cash & Equivalents high stood at $9.8 billion for Q3 2025, and its period low was $2.1 billion during Q4 2022.
  • Over the past 5 years, Eli Lilly's median Cash & Equivalents value was $3.1 billion (recorded in 2025), while the average stood at $3.3 billion.
  • As far as peak fluctuations go, Eli Lilly's Cash & Equivalents crashed by 4586.88% in 2022, and later skyrocketed by 19064.71% in 2025.
  • Quarter analysis of 5 years shows Eli Lilly's Cash & Equivalents stood at $3.8 billion in 2021, then tumbled by 45.87% to $2.1 billion in 2022, then surged by 36.36% to $2.8 billion in 2023, then increased by 15.96% to $3.3 billion in 2024, then soared by 199.59% to $9.8 billion in 2025.
  • Its last three reported values are $9.8 billion in Q3 2025, $3.4 billion for Q2 2025, and $3.1 billion during Q1 2025.